参考文献/References:
[1] Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer:initial results from the National Oncologic PET Registry[J]. J Clin Oncol, 2008, 26(13):2155-2161. DOI:10.1200/JCO.2007.14.5631.
[2] Lyons JA, Myles J, Pohlman B, et al. Treatment of prognosis of primary breast lymphoma:a review of 13 cases[J]. Am J Clin, 2000, 23(4):334-336.
[3] Rosenberg SA, Boiron M, DeVita VT, et al. Report of the Committee on Hodgkin’s Disease Staging Procedures[J]. Cancer Res, 1971, 31(11):1862-1863.
[4] Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease:Cotswolds meeting[J]. J Clin Oncol, 1989, 7(11):1630-1636. DOI:10.1200/JCO.1989.7.11.1630.
[5] Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using[18F]-fluorodeoxyglucose and positron emission tomography:review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group[J]. Eur J Cancer, 1999, 35(13):1773-1782.
[6] Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy[J]. Blood, 2016, 128(21):2489-2496. DOI:10.1182/blood-2016-05-718528.
[7] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation,staging,and response assessment of Hodgkin and non-Hodgkin lymphoma:The Lugano classication[J]. J Clin Oncol, 2014, 32(27):3059-3068. DOI:10.1200/JCO.2013.54.8800.
[8] Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria[J]. Clin Cancer Res, 2009, 15(23):7412-7420. DOI:10.1158/1078-0432.CCR-09-1624.
[9] Valls L, Badve C, Avril S, et al. FDG-PET imaging in hematological malignancies[J]. Blood Rev, 2016, 30(4):317-331. DOI:10.1016/j.blre.2016.02.003.
[10] Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography(18F-FDG-PET) and a comparison of 18F-FDG-pet with (67) gallium scintigraphy in the evaluation of lymphoma:relation to histologic subtypes based on the World Health Organization classification[J]. Cancer, 2007, 110(3):652-659. DOI:10.1002/cncr.22807.
[11] Pelosi E, Pregno P, Penna D, et al. Role of whole-body 18F fluorodeoxyglucose positron emission tomography/computed tomography(FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma[J]. Radiol Med, 2008, 113(4):578-590. DOI:10.1007/s11547-008-0264-7.
[12] Chalaye J, Luciani A, Enache C, et al. Clinical impact of contrast-enhanced computed tomography combined with low-dose 18F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management[J]. Leuk Lymphoma, 2014, 55(12):2887-2892. DOI:10.3109/10428194. 2014.900761.
[13] Adams HJ, Kwee TC, Fijnheer R, et al. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma[J]. Am J Hematol, 2014, 89(7):726-731. DOI:10.1002/ajh.23730.
[14] Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy[J]. J Nucl Med, 2013, 54(8):1244-1250. DOI:10.2967/jnumed.112.114710.
[15] Platzek I, Beuthien-Baumann B, Ordemann R, et al. FDG PET/MR for the assessment of lymph node involvement in lymphoma:initial results and role of diffusion-weighted MR[J]. Acad Radiol, 2014, 21(10):1314-1319. DOI:10.1016/j.acra.2014.05.019.
[16] Bozgeyik Z, Onur MR, Poyraz AK. The role of diffusion weighted magnetic resonance imaging in oncologic settings[J]. Quant Imaging Med Surg, 2013, 3(5):269-278. DOI:10.3978/j.issn.2223-4292. 2013.10.07.
[17] Afaq A, Fraioli F, Sidhu H, et al. Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma[J]. Clin Nucl Med, 2017, 42(1):e1-e7. DOI:10.1097/RLU.0000000000001344.
[18] de Jong A, Kwee TC, de Klerk JM, et al. Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma[J]. Am J Nucl Med Mol Imaging, 2014, 4(3):231-238.
[19] Kwee TC, Vermoolen MA, Akkerman EA, et al. Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma:comparison with CT in a prospective multicenter study[J]. J Magn Reson Imaging, 2014, 40(1):26-36. DOI:10.1002/jmri.24356.
[20] Littooij AS, Kwee TC, Barber I, et al. Whole-body MRI for initial staging of paediatric lymphoma:prospective comparison to an FDG-PET/CT-based reference standard[J]. Eur Radiol, 2014, 24(5):1153-1165. DOI:10.1007/s00330-014-3114-0.
[21] Wu LM, Chen FY, Jiang XX, et al. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma:a systematic review and meta-analysis[J]. Eur J Radiol, 2012, 81(2):303-311. DOI:10.1016/j.ejrad.2010.11.020.
[22] Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lymphoma[J]. Eur J Nucl Med Mol Imaging, 2014, 41(5):1004-1027. DOI:10.1007/s00259-013-2686-2.
[23] Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma[J]. Blood, 2006, 107(1):52-59. DOI:10.1182/blood-2005-06-2252.
[24] Ferrari C, Niccoli AA, Merenda N, et al. Pediatric Hodgkin Lymphoma:Predictive value of interim 18F-FDG PET/CT in therapy response assessment[J]. Medicine (Baltimore), 2017, 96(5):e5973. DOI:10.1097/MD.0000000000005973.
[25] Rossi C, Kanoun S, Berriolo-Riedinger A, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients[J]. J Nucl Med, 2014, 55(4):569-573. DOI:10.2967/jnumed.113.130609.
[26] Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma[J]. Ann Oncol, 2005, 16(9):1514-1523. DOI:10.1093/annonc/mdi272.
[27] Adams HJA, Kwee TC. Interim FDG-PET has no value in selecting patients who require treatment modification in both early-and advanced-stage Hodgkin lymphoma[J/OL]. Br J Haematol, 2017[2017-12-25]. https://www.ncbi.nlm.nih.gov/pubmed/28905368. DOI:10.1111/bjh.14906.
[28] Plosker GL, Figgitt DP. Rituximab:a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia[J]. Drugs, 2003, 63(8):803-843.
[29] Cheson BD, Kostakoglu L. FDG-PET for Early Response Assessment in Lymphomas:Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation[J]. Oncology (Williston Park), 2017, 31(1):71-76.
[30] Horger M, Claussen C, Kramer U, et al. Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity-a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging[J]. Eur J Radiol, 2014, 83(9):1655-1664. DOI:10.1016/j.ejrad.2014.05.027.
[31] Wu X, Nerisho S, Dastidar P, et al. Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma-a whole-body MRI and diffusion-weighted imaging study[J]. NMR Biomed, 2013, 26(9):1186-1194. DOI:10.1002/nbm.2933.
[32] Wu X, Kellokumpu-Lehtinen PL, Pertovaara H, et al. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffus e large B-cell lymphoma-a pilot study:comparison with 2-deoxy-2-fluoro-D-glucose-positron emission tomography/computed tomography[J]. NMR Biomed, 2011, 24(10):1181-1190. DOI:10.1002/nbm.1689.
[33] Cheson BD. Role of functional imaging in the management of lymphoma[J]. J Clin Oncol, 2011, 29(14):1844-1854. DOI:10.1200/JCO.2010.32.5225.
[34] Metser U, Mohan R, Beckley V, et al. FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy:A Multiparametric Approach[J]. Nucl Med Mol Imaging, 2016, 50(1):46-53. DOI:10.1007/s13139-015-0368-7.
[35] Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma[J]. Ann Oncol, 2011, 22(4):910-915. DOI:10.1093/annonc/mdq549.
[36] Cerci JJ, Trindade E, Pracchia LF, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin’s lymphoma in unconfirmed complete remission or partial remission after first-line therapy[J]. J Clin Oncol, 2010, 28(8):1415-1421. DOI:10.1200/JCO.2009.25.4367.
[37] Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial):a randomised, open-label, phase 3 non-inferiority trial[J]. Lancet, 2012, 379(9828):1791-1799. DOI:10.1016/S0140-6736(11)61940-5.
[38] Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma:consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol, 2014, 32(27):3048-3058. DOI:10.1200/JCO.2013.53.5229.
[39] De Paepe K, Bevernage C, De Keyzer F, et al. Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma:a pilot study[J]. Cancer Imaging, 2013, 13(1):53-62. DOI:10.1102/1470-7330.2013.0006.
[40] Maggialetti N, Ferrari C, Minoia C, et al. Role of WB-MR/DWIBS compared to 18F-FDG PET/CT in the therapy response assessment of lymphoma[J]. Radiol Med, 2016, 121(2):132-143. DOI:10.1007/s11547-015-0581-6.
[41] Lin C, Itti E, Luciani A, et al. Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma:pilot study[J]. Invest Radiol, 2011, 46(5):341-349. DOI:10.1097/RLI.0b013e3182087b03.
[42] Sin KM, Ho SK, Wong BY, et al. Beyond the lymph nodes:FDG-PET/CT in primary extranodal lymphoma[J]. Clin Imaging, 2017, 42:25-33. DOI:10.1016/j.clinimag.2016.11.006.
[43] Platzek I, Beuthien-Baumann B, Langner J, et al. PET/MR for therapy response evaluation in malignant lymphoma:initial experience[J]. MAGMA, 2013, 26(1):49-55. DOI:10.1007/s10334-012-0342-7.
[44] Dhilly M, Guillouet S, Patin D, et al. 2-[18F]fludarabine, a novel positron emission tomography(PET) tracer for imaging lymphoma:a micro-PET study in murine models[J]. Mol Imaging Biol, 2014,16(1):118-126. DOI:10.1007/s11307-013-0659-2.
[45] Mena E, Lindenberg ML, Turkbey BI, et al. A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy[J]. Clin Nucl Med, 2014, 39(10):874-881. DOI:10.1097/RLU.0000000000000539.
[46] Lee H, Kim SK, Kim YI, et al. Early determination of prognosis by interim3’-deoxy-3’-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma[J]. J Nucl Med, 2014, 55(2):216-222. DOI:10.2967/jnumed.113.124172.
[47] Pichler BJ, Kolb A, Nägele T, et al. PET/MRI:paving the way for the next generation of clinical multimodality imaging applications[J]. J Nucl Med, 2010, 51(3):333-336. DOI:10.2967/jnumed.109. 061853.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[5]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[6]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[11]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[12]胡娜,吴永港,肖立志,等.18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
Hu Na,Wu Yonggang,Xiao Lizhi,et al.Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
[13]戴娜,吴翼伟.影像学技术在霍奇金淋巴瘤诊疗中的价值[J].国际放射医学核医学杂志,2014,38(2):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
Dai Na,Wu Yiwei.The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
[14]杨希,党春江.泌尿系统原发性结外淋巴瘤的临床及影像学表现[J].国际放射医学核医学杂志,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
YANG Xi,DANG Chun-jiang.The clinical and imaging appearances of primary extranodal lymphoma of the urinary system[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
[15]李艳梅,杨建伟,李鹏,等.单眼虹膜原发非霍奇金淋巴瘤18F-FDGPET/CT显像及疗效评价一例[J].国际放射医学核医学杂志,2013,37(5):326.[doi:10.3760/cma.j.issn.1673-4114.2013.05.017]
[16]萨日,赵红光,关锋,等.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2013,37(1):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
SA Ri,ZHAO Hong-guang,GUAN Feng,et al.Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
[17]李倩,刘建军.18F-FDG PET-CT评价淋巴瘤疗效及预后的价值[J].国际放射医学核医学杂志,2011,35(4):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
LI Qian,LIU Jian-jun.The value of 18F-FDG PET-CT in lymphoma therapy evaluation and prognosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
[18]郑玉民,颜珏.18F-氟脱氧葡萄糖PET在恶性淋巴瘤中的应用[J].国际放射医学核医学杂志,2008,32(6):347.
ZHENG Yu-min,YAN Jue.The role of 18F-fluorodeoxyglucoxe PET in malignant lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):347.
[19]秦文琼,高硕.PET/CT与临床预后因素在弥漫大B细胞淋巴瘤疗效评价及预后评估中的应用[J].国际放射医学核医学杂志,2017,41(6):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
Qin Wenqiong,Gao Shuo.Application of PET/CT and clinical factors in the therapeutic and prognostic evaluation of diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
[20]段钰,邓小虎,徐迟峰,等.面部原发性外周T细胞淋巴瘤-非特指型18F-FDG PET/CT显像一例[J].国际放射医学核医学杂志,2017,41(6):455.[doi:10.3760/cma.j.issn.1673-4114.2017.06.014]